Canada markets close in 1 hour 28 minutes
  • S&P/TSX

    20,198.60
    -2.05 (-0.01%)
     
  • S&P 500

    4,248.59
    +2.15 (+0.05%)
     
  • DOW

    33,917.52
    -28.06 (-0.08%)
     
  • CAD/USD

    0.8130
    +0.0004 (+0.04%)
     
  • CRUDE OIL

    73.03
    +0.18 (+0.25%)
     
  • BTC-CAD

    41,002.68
    +441.89 (+1.09%)
     
  • CMC Crypto 200

    799.97
    -10.23 (-1.26%)
     
  • GOLD FUTURES

    1,781.40
    +4.00 (+0.23%)
     
  • RUSSELL 2000

    2,313.03
    +17.08 (+0.74%)
     
  • 10-Yr Bond

    1.4890
    +0.0170 (+1.15%)
     
  • NASDAQ

    14,279.10
    +25.83 (+0.18%)
     
  • VOLATILITY

    16.23
    -0.43 (-2.58%)
     
  • FTSE

    7,074.06
    -15.95 (-0.22%)
     
  • NIKKEI 225

    28,874.89
    -9.24 (-0.03%)
     
  • CAD/EUR

    0.6810
    +0.0006 (+0.09%)
     

Sanofi & GSK COVID Vaccine Shows Positive Result in Phase-2 Trials

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

French pharmaceutical company Sanofi and Britain's GSK announced on Monday, May 17, that their vaccine candidate had “achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a phase-2 study with 722 volunteers.”

It said in a statement, "A global pivotal phase-3 study is expected to start in the coming weeks."

"“Our phase-2 data confirms the potential of this vaccine to play a role in addressing this ongoing global public health crisis.”" - Thomas Triomphe, Executive Vice-President and Global Head of Sanofi Pasteur

He added, “As we know multiple vaccines will be needed, especially as variants continue to emerge, and the requirement for effective booster vaccines that can be stored at normal temperatures, increases.”

Also Read: Sanofi & GSK COVID Vaccine Delayed, To Be Out Only by End of 2021

The statement added, “After a single injection, high neutralising antibody levels were generated in participants with evidence of prior SARS-CoV-2 infection, suggesting strong potential for development as a booster vaccine.”

The phase-3 trial is expected to enrol more than 35,000 adult participants from a broad range of countries and will assess the efficacy of two vaccine formulations

The partnership between Sanofi and GSK, is combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK’s adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.

Sanofi is also committed to providing manufacturing support to other vaccine producers.

The company recently announced it will manufacture up to 200 million doses of Moderna’s COVID-19 vaccine for the US, starting in September. Earlier this year, Sanofi had announced that the company will provide support to BioNTech for 125 million doses for the European Union.

In February, Sanofi said it would support Johnson & Johnson for the production of its COVID-19 vaccine at a rate of approximately 12 million doses per month.

Also Read: 17 Arrested in Delhi Over Posters Critical of PM’s Vaccine Exports

. Read more on COVID-19 by The Quint.For 91-Year-Old Active Cricketer Crowell, Age is Just a NumberSanofi & GSK COVID Vaccine Shows Positive Result in Phase-2 Trials . Read more on COVID-19 by The Quint.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting